Latest news
Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program - tradingview.comtradingview.com · Thu, 06 Aug 2026 06:00:00 GMTGlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development - PR NewswirePR Newswire · Mon, 03 Aug 2026 01:00:00 GMT